Roche's Class 1 Innovative Drug Risdiplam for Oral Solution Receives NMPA Approval for Spinal Muscular Atrophy in China

On June 17, the National Medical Products Administration (NMPA) announced that, through the priority review and approval procedure, it has approved the marketing of risdiplam powder for oral solution, a Class 1 innovative drug submitted by Roche. This product is a treatment for pediatric rare diseases, indicated for spinal muscular atrophy (SMA) in patients aged 2 months and older.

Spinal muscular atrophy is a hereditary neuromuscular disease caused by mutations in the survival motor neuron 1 (SMN1) gene, which results in functional deficiency of the SMN protein. It is one of the autosomal recessive genetic diseases causing infant mortality and has been included in the 《First Catalog of Rare Diseases》 jointly issued by the National Health Commission and four other departments. Risdiplam directly targets the underlying molecular defect of the disease, increasing the production of functional SMN protein in both central and peripheral tissues. The market launch of this product provides a new treatment option for patients with spinal muscular atrophy.